#USA #New York #Mayo Clinic #Aignostics #Pathology Model

Aignostics and Mayo Clinic: A Pathology Revolution

In a significant leap for the field of digital pathology, Aignostics has unveiled the results of a groundbreaking model developed in cooperation with the renowned Mayo Clinic. The innovative model, crafted in just two months, harnesses an impressive dataset of 1.2 million varied slide images from both Mayo Clinic and Charité – Universitätsmedizin Berlin. This effort has resulted in a new benchmark in performance across more than 20 public reference points, enhancing the capabilities of existing models in the market.

Efficiency and Performance Redefined

The newfound model demonstrates not only high accuracy but also computational efficiency, making it more user-friendly compared to prior image-based models. This remarkable combination of performance and efficiency was achieved through a meticulous development process infused with expertise from Aignostics’ pathologists. Their emphasis on integrating specialized medical knowledge throughout the model-building process played a pivotal role in this success.

“We are thrilled by these outcomes from our collaboration with Mayo Clinic,” said Maximilian Alber, Chief Technology Officer at Aignostics. “The direct access to millions of additional training images and new data modalities will allow us to progressively enhance the model's capabilities and accuracy over time.”

Implications for the Healthcare Industry

The new model is set to become a vital tool for healthcare organizations and biological sciences, facilitating both research and clinical development. Aignostics plans to embed this advanced model within its expanding portfolio of AI-based pathology products, which are tailored to offer precise and universally applicable solutions for tissue, cell, and biomarker image analyses. This dual approach—licensing of core technology and specific application offerings—enables partner organizations to utilize the model’s capabilities in ways that align with their unique requirements.

A Future-Focused Collaboration

In a statement reflecting their aspirations, Jim Rogers, CEO of Mayo Clinic Digital Pathology, remarked, “We will collaborate with Aignostics to redefine pathology for patients globally. These results reveal the immense potential that lies in combining Mayo Clinic's extensive medical expertise and resources with Aignostics' cutting-edge technologies.” Viktor Matyas, CEO of Aignostics, echoed this sentiment by emphasizing their shared ambition to co-lead advancements in the field.

About Aignostics

Founded in 2018, Aignostics is an artificial intelligence company dedicated to transforming complex pathological data into actionable insights. By blending exclusive access to multimodal clinical data, industry-leading technologies, and rigorous scientific inquiry, Aignostics aims to deliver premier products and services that cater to the next generation of precision medicine. Their collaboration with biopharmaceutical partners supports drug discovery, translational research, clinical trials, and the development of Companion Diagnostics (CDx).

With operations in Berlin and New York, Aignostics is positioned to influence both the local and global healthcare landscapes significantly. For more information, visit Aignostics' official website and follow them on LinkedIn.